Laboratory of Genomics of Antitumor Adaptive Immunity, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Genomics of Adaptive Immunity Department, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Nat Rev Immunol. 2020 May;20(5):294-307. doi: 10.1038/s41577-019-0257-x. Epub 2020 Jan 27.
Recent data show that B cells and plasma cells located in tumours or in tumour-draining lymph nodes can have important roles in shaping antitumour immune responses. In tumour-associated tertiary lymphoid structures, T cells and B cells interact and undergo cooperative selection, specialization and clonal expansion. Importantly, B cells can present cognate tumour-derived antigens to T cells, with the functional consequences of such interactions being shaped by the B cell phenotype. Furthermore, the isotype and specificity of the antibodies produced by plasma cells can drive distinct immune responses. Here we summarize our current knowledge of the roles of B cells and antibodies in the tumour microenvironment. Moreover, we discuss the potential of using immunoglobulin repertoires as a source of tumour-specific receptors for immunotherapy or as biomarkers to predict the efficacy of immunotherapeutic interventions.
最近的数据表明,位于肿瘤或肿瘤引流淋巴结中的 B 细胞和浆细胞在塑造抗肿瘤免疫反应方面可以发挥重要作用。在肿瘤相关的三级淋巴结构中,T 细胞和 B 细胞相互作用并经历协同选择、特化和克隆扩增。重要的是,B 细胞可以将同源的肿瘤衍生抗原呈递给 T 细胞,这种相互作用的功能后果受到 B 细胞表型的影响。此外,浆细胞产生的抗体的同型和特异性可以驱动不同的免疫反应。在这里,我们总结了我们目前对 B 细胞和抗体在肿瘤微环境中的作用的认识。此外,我们还讨论了利用免疫球蛋白库作为肿瘤特异性受体用于免疫治疗的潜在用途,或作为预测免疫治疗干预效果的生物标志物。